Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study.

Yuan L, Wang Q, Sun F, Yang W, Lei J, Liu J, Fan Y, Shan Y, Lu Y, Zhang Y, Wang Y, Zhu J, Guo L, Chen W, Lu S, Shi H

Open source

DOI
10.3389/fimmu.2026.1792179
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1792179,
  title = {Inferring tumor immune microenvironment -related risk states from pretreatment H\&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study.},
  author = {Yuan L and Wang Q and Sun F and Yang W and Lei J and Liu J and Fan Y and Shan Y and Lu Y and Zhang Y and Wang Y and Zhu J and Guo L and Chen W and Lu S and Shi H},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1792179},
  url = {https://doi.org/10.3389/fimmu.2026.1792179}
}

RIS

TY  - JOUR
TI  - Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study.
AU  - Yuan L
AU  - Wang Q
AU  - Sun F
AU  - Yang W
AU  - Lei J
AU  - Liu J
AU  - Fan Y
AU  - Shan Y
AU  - Lu Y
AU  - Zhang Y
AU  - Wang Y
AU  - Zhu J
AU  - Guo L
AU  - Chen W
AU  - Lu S
AU  - Shi H
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1792179
UR  - https://doi.org/10.3389/fimmu.2026.1792179
ER  - 

APA

L, Y., Q, W., F, S., W, Y., J, L., J, L., Y, F., Y, S., Y, L., Y, Z., Y, W., J, Z., L, G., W, C., S, L., & H, S. (2026). Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1792179

Source records